Liposomes and nanotechnology in drug development: focus on oncotargets

Tomohiro Kozako,1 Naomichi Arima,2 Makoto Yoshimitsu,3 Shin-Ichro Honda,1 Shinji Soeda11Department of Biochemistry, Faculty of Pharmaceutical Sciences, Fukuoka University, Fukuoka, Japan; 2Division of Hematology and Immunology, Center for Chronic Viral Diseases, Graduate School of Medical and Dental...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Kozako T, Arima N, Yoshimitsu M, Honda S-I, Soeda S
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2012
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/8c2e3d94c0914b7d9b72ebbfab18f9d1
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:8c2e3d94c0914b7d9b72ebbfab18f9d1
record_format	dspace
spelling	oai:doaj.org-article:8c2e3d94c0914b7d9b72ebbfab18f9d12021-12-02T01:23:33ZLiposomes and nanotechnology in drug development: focus on oncotargets1176-91141178-2013https://doaj.org/article/8c2e3d94c0914b7d9b72ebbfab18f9d12012-09-01T00:00:00Zhttp://www.dovepress.com/liposomes-and-nanotechnology-in-drug-development-focus-on-oncotargets-a11000https://doaj.org/toc/1176-9114https://doaj.org/toc/1178-2013Tomohiro Kozako,1 Naomichi Arima,2 Makoto Yoshimitsu,3 Shin-Ichro Honda,1 Shinji Soeda11Department of Biochemistry, Faculty of Pharmaceutical Sciences, Fukuoka University, Fukuoka, Japan; 2Division of Hematology and Immunology, Center for Chronic Viral Diseases, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan; 3Department of Hematology and Immunology, Kagoshima University Hospital, Kagoshima, JapanAbstract: Nanotechnology is the development of an engineered device at the atomic, molecular, and macromolecular level in the nanometer range. Advances in nanotechnology have proven beneficial in therapeutic fields such as drug-delivery and gene/protein delivery. Antigen delivery systems are important for inducing and modifying immune responses. In cellular immunity, cytotoxic T lymphocytes (CTLs) are important in the host defense against tumors. Key to the development of CTL-inducible vaccines is the ability to deliver antigens to antigen-presenting cells efficiently and to induce the subsequent activation of T cell-mediated immunity without adjuvants, as they can induce excessive inflammation leading to systemic febrile disease. Since expression and cloning methods for tumor-associated antigens have been reported, cancer vaccines that induce effective cell immunity may be promising therapeutic candidates, but Th2 cells are undesirable for use in cancer immunotherapy. Peptide vaccines have immunological and economic advantages as cancer vaccines because CTL epitope peptides from tumor-associated antigens have high antigen-specificity. However, cancer vaccines have had limited effectiveness in clinical responses due to the ability of cancer cells to &ldquo;escape&rdquo; from cancer immunity and a low efficiency of antigen-specific CTL induction due to immunogenic-free synthetic peptides. In contrast, carbohydrate-decorated particles such as carbohydrate-coated liposomes with encapsulated antigens might be more suitable as antigen delivery vehicles to antigen-presenting cells. Oligomannose-coated liposomes (OML) can eliminate established tumors in mouse cancer models. In addition, OMLs with an encased antigen can induce antigen-specific CTLs from peripheral blood mononuclear cells obtained from patients. Feasibility studies of OML-based vaccines have revealed their potential for clinical use as vaccines for diseases where CTLs act as effector cells. Furthermore, use of the hepatitis B core particle, in which tumor-antigen epitopes are set, has consistently been shown to induce strong CTL responses without the use of an adjuvant. Thus, nanoparticles may provide a new prophylactic strategy for infectious disease and therapeutic approaches for cancer via the induction of T-cell immunity.Keywords: adult T cell leukemia, cytotoxic T lymphocytes, oligomannose-coated liposomes, vaccineKozako TArima NYoshimitsu MHonda S-ISoeda SDove Medical PressarticleMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol 2012, Iss default, Pp 4943-4951 (2012)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Kozako T Arima N Yoshimitsu M Honda S-I Soeda S Liposomes and nanotechnology in drug development: focus on oncotargets
description	Tomohiro Kozako,1 Naomichi Arima,2 Makoto Yoshimitsu,3 Shin-Ichro Honda,1 Shinji Soeda11Department of Biochemistry, Faculty of Pharmaceutical Sciences, Fukuoka University, Fukuoka, Japan; 2Division of Hematology and Immunology, Center for Chronic Viral Diseases, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan; 3Department of Hematology and Immunology, Kagoshima University Hospital, Kagoshima, JapanAbstract: Nanotechnology is the development of an engineered device at the atomic, molecular, and macromolecular level in the nanometer range. Advances in nanotechnology have proven beneficial in therapeutic fields such as drug-delivery and gene/protein delivery. Antigen delivery systems are important for inducing and modifying immune responses. In cellular immunity, cytotoxic T lymphocytes (CTLs) are important in the host defense against tumors. Key to the development of CTL-inducible vaccines is the ability to deliver antigens to antigen-presenting cells efficiently and to induce the subsequent activation of T cell-mediated immunity without adjuvants, as they can induce excessive inflammation leading to systemic febrile disease. Since expression and cloning methods for tumor-associated antigens have been reported, cancer vaccines that induce effective cell immunity may be promising therapeutic candidates, but Th2 cells are undesirable for use in cancer immunotherapy. Peptide vaccines have immunological and economic advantages as cancer vaccines because CTL epitope peptides from tumor-associated antigens have high antigen-specificity. However, cancer vaccines have had limited effectiveness in clinical responses due to the ability of cancer cells to &ldquo;escape&rdquo; from cancer immunity and a low efficiency of antigen-specific CTL induction due to immunogenic-free synthetic peptides. In contrast, carbohydrate-decorated particles such as carbohydrate-coated liposomes with encapsulated antigens might be more suitable as antigen delivery vehicles to antigen-presenting cells. Oligomannose-coated liposomes (OML) can eliminate established tumors in mouse cancer models. In addition, OMLs with an encased antigen can induce antigen-specific CTLs from peripheral blood mononuclear cells obtained from patients. Feasibility studies of OML-based vaccines have revealed their potential for clinical use as vaccines for diseases where CTLs act as effector cells. Furthermore, use of the hepatitis B core particle, in which tumor-antigen epitopes are set, has consistently been shown to induce strong CTL responses without the use of an adjuvant. Thus, nanoparticles may provide a new prophylactic strategy for infectious disease and therapeutic approaches for cancer via the induction of T-cell immunity.Keywords: adult T cell leukemia, cytotoxic T lymphocytes, oligomannose-coated liposomes, vaccine
format	article
author	Kozako T Arima N Yoshimitsu M Honda S-I Soeda S
author_facet	Kozako T Arima N Yoshimitsu M Honda S-I Soeda S
author_sort	Kozako T
title	Liposomes and nanotechnology in drug development: focus on oncotargets
title_short	Liposomes and nanotechnology in drug development: focus on oncotargets
title_full	Liposomes and nanotechnology in drug development: focus on oncotargets
title_fullStr	Liposomes and nanotechnology in drug development: focus on oncotargets
title_full_unstemmed	Liposomes and nanotechnology in drug development: focus on oncotargets
title_sort	liposomes and nanotechnology in drug development: focus on oncotargets
publisher	Dove Medical Press
publishDate	2012
url	https://doaj.org/article/8c2e3d94c0914b7d9b72ebbfab18f9d1
work_keys_str_mv	AT kozakot liposomesandnanotechnologyindrugdevelopmentfocusononcotargets AT ariman liposomesandnanotechnologyindrugdevelopmentfocusononcotargets AT yoshimitsum liposomesandnanotechnologyindrugdevelopmentfocusononcotargets AT hondasi liposomesandnanotechnologyindrugdevelopmentfocusononcotargets AT soedas liposomesandnanotechnologyindrugdevelopmentfocusononcotargets
_version_	1718403149276905472

Liposomes and nanotechnology in drug development: focus on oncotargets

Ejemplares similares